| Description | TGFβRI-IN-1 is an oral active and selective inhibitor of TGFβ receptor type I (TGFβRI) kinase(IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively ). |
| In vitro | various cellular responses regulated by Transforming Growth Factor-β signaling such as cell proliferation, differentiation, cell migration and cell death. TGF-β has at least three isoforms TGF-β1, TGF-β2 and TGF-β3. TGF-β1 is two well-conserved single membrane serine/threonine kinase type I (ALK5). ALK5 inhibitos can be used for treating fibrotic disease, tumor, inflammatory disease, and autoimmune disease. |
| Target activity | TGFβRI:2 nM |
| molecular weight | 362.4 |
| Molecular formula | C20H14D3N5O2 |
| CAS | 1950628-94-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Yong Zhang, et al. Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents. ACS Med. Chem. Lett.20189111117-1122. |